Sign In
Buy JNJ
$231.29
+2.90 (+1.27%)
At Close: Jun 22, 2026
Johnson & Johnson $JNJ Shares Bought by KBC Group NV
05:34am, Monday, 20'th Apr 2026
KBC Group NV raised its holdings in Johnson and Johnson (NYSE: JNJ) by 21.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,296,831 shares
BCS Wealth Management Increases Stake in Johnson & Johnson $JNJ
03:51am, Sunday, 19'th Apr 2026
BCS Wealth Management grew its position in Johnson and Johnson (NYSE: JNJ) by 93.2% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchang
Is Johnson & Johnson a Buy After Its Q1 2026 Earnings Report?
08:30am, Saturday, 18'th Apr 2026
Johnson & Johnson exceeded expectations in its Q1 2026 earnings report. Investors weren't blown away by the results.
What Moved Markets This Week
06:44am, Saturday, 18'th Apr 2026
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Farther Finance Advisors LLC Acquires 23,522 Shares of Johnson & Johnson $JNJ
06:41am, Saturday, 18'th Apr 2026
Farther Finance Advisors LLC boosted its holdings in Johnson and Johnson (NYSE: JNJ) by 28.4% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Com
Atwater Malick LLC Trims Holdings in Johnson & Johnson $JNJ
04:05am, Saturday, 18'th Apr 2026
Atwater Malick LLC lowered its holdings in Johnson and Johnson (NYSE: JNJ) by 14.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The
US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims
10:36pm, Friday, 17'th Apr 2026
A U.S. judge has rejected Bayer's request for an injunction to block Johnson & Johnson's alleged false advertising that its multibillion-dollar drug cuts the risk of death from prostate cancer in h
U.S. judge rejects Bayer's bid to block Johnson & Johnson prostate cancer drug claims
07:00pm, Friday, 17'th Apr 2026
A federal judge rejected Bayer's request for an injunction to block Johnson & Johnson's alleged false advertising that its multibillion-dollar drug cuts the risk of death from prosta
Johnson & Johnson: Why I See Downside Ahead
10:42am, Friday, 17'th Apr 2026
Johnson & Johnson only slightly raised its 2026 financial guidance. So JNJ expects its operational sales to be between $99.7 billion and $100.7 billion, up from $99.5 billion to $100.5 billion. In my
5 Dividend Stocks Boost Payouts as Markets Reel Under Inflation Fears
08:52am, Friday, 17'th Apr 2026
SKT and peers boost dividends as inflation rates and geopolitical risks drive demand for steady income plays in a volatile market.
JM2 Capital Inc. Acquires New Shares in Johnson & Johnson $JNJ
04:06am, Friday, 17'th Apr 2026
JM2 Capital Inc. acquired a new stake in shares of Johnson and Johnson (NYSE: JNJ) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange C
Fourpath Capital Management LLC Has $8.27 Million Holdings in Johnson & Johnson $JNJ
04:06am, Friday, 17'th Apr 2026
Fourpath Capital Management LLC trimmed its holdings in Johnson and Johnson (NYSE: JNJ) by 6.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities a
This "Boring" Dividend King Is Quietly Turning Into a Growth Machine
03:28pm, Thursday, 16'th Apr 2026
J&J's stock has rallied over the past 12 months. It's a solid safe-haven stock, but it could have more upside than its peers.
3 Healthcare Stocks That Have Held Up in Every Market Downturn
01:47pm, Thursday, 16'th Apr 2026
This trio has typically outpaced the S&P 500 in economic downturns. The three are healthcare leaders with plenty of size and diversity.
Coca-Cola vs. Johnson & Johnson: The Safest Dividend on Wall Street Might Surprise You
12:26pm, Thursday, 16'th Apr 2026
Coca-Cola (NYSE:KO | KO Price Prediction) closed 2025 with steady organic growth and a 63rd consecutive dividend increase, while Johnson & Johnson (NYSE:JNJ) opened 2026 with accelerating pharmaceutic
